Literature DB >> 24273632

Design, Synthesis, and Anti-leukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya).

Rebecca Fransson1, Alison N McCracken, Bin Chen, Ryan J McMonigle, Aimee L Edinger, Stephen Hanessian.   

Abstract

FTY720 functions as an immunosuppressant due to its effect on sphingosine-1-phosphate receptors. At doses well above those needed for immunosuppression, FTY720 also has anti-neoplastic actions. Our published work suggests that at least some of FTY720's anti-cancer activity is independent of its effects on S1P receptors and due instead to its ability to induce nutrient transporter down-regulation. Compounds that trigger nutrient transporter loss but lack FTY720's S1P receptor-related, dose-limiting toxicity have the potential to be effective and selective anti-tumor agents. In this study, a series of enantiomerically pure and stereochemically diverse O-substituted benzyl ethers of pyrrolidines was generated and tested for the ability to kill human leukemia cells. The stereochemistry of the hydroxymethyl was found to be a key determinant of compound activity. Moreover, phosphorylation of this group was not required for anti-leukemic activity.

Entities:  

Keywords:  FTY720; arylmethyl ether; leukemia; pyrrolidine

Year:  2013        PMID: 24273632      PMCID: PMC3834958          DOI: 10.1021/ml4002425

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  19 in total

1.  Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.

Authors:  Kenneth LaMontagne; Amanda Littlewood-Evans; Christian Schnell; Terence O'Reilly; Lorenza Wyder; Teresa Sanchez; Beatrice Probst; Jeannene Butler; Alexander Wood; Gene Liau; Eric Billy; Andreas Theuer; Timothy Hla; Jeanette Wood
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.

Authors:  Jeremy J Clemens; Michael D Davis; Kevin R Lynch; Timothy L Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2005-08-01       Impact factor: 2.823

3.  Sphingosine 1-phosphate analogs as receptor antagonists.

Authors:  Michael D Davis; Jeremy J Clemens; Timothy L Macdonald; Kevin R Lynch
Journal:  J Biol Chem       Date:  2004-12-08       Impact factor: 5.157

4.  Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models.

Authors:  Haruhito Azuma; Shiro Takahara; Naotsugu Ichimaru; Jing Ding Wang; Yuko Itoh; Yoshinori Otsuki; Junji Morimoto; Ryosuke Fukui; Masaaki Hoshiga; Tadashi Ishihara; Norio Nonomura; Seiichi Suzuki; Akihiko Okuyama; Yoji Katsuoka
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

5.  FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer.

Authors:  Chee-Wai Chua; Davy Tak-Wing Lee; Ming-Tat Ling; Chun Zhou; Kwan Man; Joanna Ho; Franky L Chan; Xianghong Wang; Yong-Chuan Wong
Journal:  Int J Cancer       Date:  2005-12-20       Impact factor: 7.396

6.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors.

Authors:  Stephen Hanessian; Guillaume Charron; Andreas Billich; Danilo Guerini
Journal:  Bioorg Med Chem Lett       Date:  2006-10-10       Impact factor: 2.823

8.  Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.

Authors:  M Germana Sanna; Jiayu Liao; Euijung Jo; Christopher Alfonso; Min-Young Ahn; Melissa S Peterson; Bill Webb; Sophie Lefebvre; Jerold Chun; Nathanael Gray; Hugh Rosen
Journal:  J Biol Chem       Date:  2004-01-19       Impact factor: 5.157

9.  A photoreactive analogue of the immunosuppressant FTY720.

Authors:  Chaode Sun; Robert Bittman
Journal:  J Org Chem       Date:  2006-03-03       Impact factor: 4.354

Review 10.  FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.

Authors:  Volker Brinkmann
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

View more
  7 in total

1.  Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in Vivo.

Authors:  Bin Chen; Saurabh G Roy; Ryan J McMonigle; Andrew Keebaugh; Alison N McCracken; Elizabeth Selwan; Rebecca Fransson; Daniel Fallegger; Andrea Huwiler; Michael T Kleinman; Aimee L Edinger; Stephen Hanessian
Journal:  ACS Chem Biol       Date:  2015-12-14       Impact factor: 5.100

Review 2.  Attacking the supply wagons to starve cancer cells to death.

Authors:  Elizabeth M Selwan; Brendan T Finicle; Seong M Kim; Aimee L Edinger
Journal:  FEBS Lett       Date:  2016-03-22       Impact factor: 4.124

Review 3.  The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.

Authors:  Sathya Narayanan Patmanathan; Lee Fah Yap; Paul G Murray; Ian C Paterson
Journal:  J Cell Mol Med       Date:  2015-07-14       Impact factor: 5.310

4.  In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.

Authors:  Jean-Baptiste Garsi; Lorenzo Sernissi; Vito Vece; Stephen Hanessian; Alison N McCracken; Grigor Simitian; Aimee L Edinger
Journal:  Eur J Med Chem       Date:  2018-09-21       Impact factor: 6.514

5.  Dynamic Phosphoproteomics Uncovers Signaling Pathways Modulated by Anti-oncogenic Sphingolipid Analogs.

Authors:  Peter Kubiniok; Brendan T Finicle; Fanny Piffaretti; Alison N McCracken; Michael Perryman; Stephen Hanessian; Aimee L Edinger; Pierre Thibault
Journal:  Mol Cell Proteomics       Date:  2018-11-27       Impact factor: 5.911

Review 6.  The emerging role of FTY720 (Fingolimod) in cancer treatment.

Authors:  Christopher White; Heba Alshaker; Colin Cooper; Matthias Winkler; Dmitri Pchejetski
Journal:  Oncotarget       Date:  2016-04-26

7.  Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.

Authors:  A N McCracken; R J McMonigle; J Tessier; R Fransson; M S Perryman; B Chen; A Keebaugh; E Selwan; S A Barr; S M Kim; S G Roy; G Liu; D Fallegger; L Sernissi; C Brandt; N Moitessier; A J Snider; S Clare; M Müschen; A Huwiler; M T Kleinman; S Hanessian; A L Edinger
Journal:  Leukemia       Date:  2016-08-30       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.